Overview

A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) along with safety and tolerability.

Phase:

Phase 3

Details

Lead Sponsor:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Paliperidone Palmitate
Risperidone